Heavyweights

Exclusive By Matthew Herper

One of the world’s best drug hunters went after Alzheimer’s. Here’s how he lost

Heavyweights By Matthew Herper

The entrepreneur behind the cancer immunotherapy revolution

Heavyweights By Rick Berke

Billionaire Sean Parker calls China’s gene-edited babies ‘Sputnik 2.0,’ praises FDA, and offers career advice for millennials

Heavyweights By Sharon Begley

‘I really don’t know what happened to Jim’: Friends ask where James Watson’s odious attitudes about race came from

Heavyweights By Sharon Begley

A pioneer in cancer immunotherapy sees a future where vaccines, CAR-T, and checkpoint inhibitors come together

Heavyweights By Ed Silverman and Kate Sheridan

How Pfizer’s CEO flew under the political radar with price hikes — until he tangled with Trump

Heavyweights By Rob Waters

Her bio reads like Silicon Valley fan fiction. At 23, she’s investing millions in the quest to defy death

Heavyweights By Andrew Joseph

He takes on Eric Lander, and the scientific establishment. ‘This is who I am. I get angry.’

Heavyweights By Megan Thielking

Meet Nature’s new editor: a geneticist who reads scientific papers like ‘page turners’

Heavyweights By Helen Branswell

The virus hunter: In a bygone era, C.J. Peters learned how to bend the rules

Heavyweights By Andrew Joseph

A veteran New York litigator is taking on opioid makers. They have a history

Heavyweights By Sharon Begley

Not just for CRISPR: Lemelson-MIT Prize honors Feng Zhang for ‘big ideas that change fields’

Heavyweights By Meghana Keshavan

Armed with science (and snark), a gynecologist takes on Trump, Goop, and all manner of bizarre health trends

First Opinion By Margaret Chan

My decade leading the WHO: dirty fights and steps toward universal coverage

Heavyweights By Sharon Begley

CRISPR pioneer Doudna envisions a world of woolly mammoths and unicorns

Heavyweights By Eric Boodman

Andy Slavitt can’t stop: How a health care wonk became a rabble-rouser

Heavyweights By Bryan Marquard and Robert Weisman — Boston Globe

Henri Termeer, biotech leader who built Genzyme into an industry giant, dies at 71

Heavyweights By Meghana Keshavan

Trump’s pick to run mental health is poised to shake things up. Even some liberals can’t wait

Heavyweights By Sharon Begley

She’s hellbent on solving the organ shortage with ‘designer pigs.’ Just don’t keep her waiting

Heavyweights By Damian Garde

One brash idea to save the drug industry — and (maybe) make a few billion dollars

Heavyweights By Casey Ross

She’s calling for a health care revolution. The radical first step: listen to patients

Heavyweights By Sheila Kaplan

‘Tough as nails’: Storm swirls around FDA drug cop who approved controversial drug

Heavyweights By Rebecca Robbins

The drug pricing crusader at the center of one of the nastiest fights of the election season

Heavyweights By Helen Branswell

For the head of Doctors Without Borders, impatience is a virtue

Heavyweights By Rob Waters

Distrustful of authority, a Holocaust survivor became a fierce critic of medical establishment